Michel Detheux I Teos Therapeutics, Inc. (ITOS) insider trading activity

Michel Detheux is Chief Executive Officer of iTeos Therapeutics, Inc.. Currently has a direct ownership of 135,903 shares of ITOS, which is worth approximately $1.38 Million. The most recent transaction as insider was on Jun 10, 2025, when has been sold 8,400 shares (Common Stock) at a price of $10.02 per share, resulting in proceeds of $84,168. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 136K

0% 3M change

130.72% 12M change

Total Value Held $1.38 Million

Michel Detheux Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 10 2025	SELL Open market or private sale	$84,168 $10.02 p/Share	8,400 Reduced 5.82%	135,903 Common Stock
Jun 10 2025	BUY Exercise of conversion of derivative security	$113,520 $4.3 p/Share	26,400 Added 14.64%	153,903 Common Stock
Jun 09 2025	SELL Open market or private sale	$84,252 $10.03 p/Share	8,400 Reduced 5.82%	135,903 Common Stock
Jun 09 2025	BUY Exercise of conversion of derivative security	$36,120 $4.3 p/Share	8,400 Added 5.5%	144,303 Common Stock
Jun 06 2025	SELL Open market or private sale	$85,764 $10.21 p/Share	8,400 Reduced 5.82%	135,903 Common Stock
Jun 06 2025	BUY Exercise of conversion of derivative security	$36,120 $4.3 p/Share	8,400 Added 5.5%	144,303 Common Stock
Jun 05 2025	SELL Open market or private sale	$85,260 $10.15 p/Share	8,400 Reduced 5.82%	135,903 Common Stock
Jun 05 2025	BUY Exercise of conversion of derivative security	$36,120 $4.3 p/Share	8,400 Added 5.5%	144,303 Common Stock
Jun 04 2025	SELL Open market or private sale	$84,840 $10.1 p/Share	8,400 Reduced 5.82%	135,903 Common Stock
Jun 04 2025	BUY Exercise of conversion of derivative security	$36,120 $4.3 p/Share	8,400 Added 5.5%	144,303 Common Stock
Mar 07 2025	BUY Grant, award, or other acquisition	-	77,000 Added 36.17%	135,903 Common Stock
Dec 05 2023	BUY Grant, award, or other acquisition	-	30,000 Added 33.74%	58,903 Common Stock
Apr 18 2022	SELL Open market or private sale	$370,990 $32.26 p/Share	11,500 Reduced 30.45%	26,263 Common Stock
Apr 18 2022	BUY Exercise of conversion of derivative security	$48,645 $4.23 p/Share	11,500 Added 23.34%	37,763 Common Stock
Mar 22 2022	SELL Open market or private sale	$641,976 $34.82 p/Share	18,437 Reduced 41.25%	26,263 Common Stock
Mar 11 2022	BUY Grant, award, or other acquisition	-	10,000 Added 18.28%	44,700 Common Stock
Feb 23 2022	SELL Open market or private sale	$504,745 $34.81 p/Share	14,500 Reduced 29.47%	34,700 Common Stock
Jan 25 2022	SELL Open market or private sale	$519,535 $35.83 p/Share	14,500 Reduced 22.76%	49,200 Common Stock
Dec 22 2021	SELL Open market or private sale	$724,102 $44.8 p/Share	16,163 Reduced 20.24%	63,700 Common Stock
Dec 22 2021	BUY Exercise of conversion of derivative security	$7,151 $4.3 p/Share	1,663 Added 2.04%	79,863 Common Stock
Dec 21 2021	SELL Open market or private sale	$857,672 $44.61 p/Share	19,226 Reduced 19.73%	78,200 Common Stock
Dec 21 2021	BUY Exercise of conversion of derivative security	$82,672 $4.3 p/Share	19,226 Added 16.48%	97,426 Common Stock
Dec 20 2021	SELL Open market or private sale	$400,337 $43.94 p/Share	9,111 Reduced 10.44%	78,200 Common Stock
Dec 20 2021	BUY Exercise of conversion of derivative security	$39,177 $4.3 p/Share	9,111 Added 9.45%	87,311 Common Stock
Nov 23 2021	SELL Open market or private sale	$523,160 $36.08 p/Share	14,500 Reduced 15.64%	78,200 Common Stock

Also insider at

VOR

Vor Biopharma Inc. Healthcare

Michel Detheux

Chief Executive Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITOS shares.

Notify only if

Value

Insider Trading

Get notified when an I Teos Therapeutics, Inc. insider buys or sells ITOS shares.

Notify only if

Operation

Value

Type

News

Receive news related to iTeos Therapeutics, Inc.

Track Activities on ITOS

Account